Diagnosis, prophylaxis and treatment of central nervous system involvement by non-Hodgkin lymphoma in HIV-infected patients;Diagnóstico, profilaxis y tratamiento de la afectación del sistema nervioso central por linfoma no hodgkiniano en pacientes con infección por el virus de la inmunodeficiencia humana

Medicina Clinica

Volumn 135, Issue 9, 2010, Pages 417-422

  Miralles, Pilar ^a   Berenguer, Juan ^a   Ribera, Josep Maria ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

AIDS; Central nervous system; Flow cytometry; HIV; Meningeal prophylaxis; Non Hodgkin lymphoma

Indexed keywords

CYTARABINE; METHOTREXATE;

CANCER RELAPSE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID EXAMINATION; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MENINGEAL LYMPHOMA; MENINGIOMA; NONHODGKIN LYMPHOMA; PROPHYLAXIS; REVIEW; SENSITIVITY AND SPECIFICITY;

CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN;

EID: 77956342983     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.04.047     Document Type: Review

References (35)

1. E.S. Jaffe, N.L. Harris, H. Stein, and J.W. Vardiman World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001 International Agency for Research on Cancer (IARC) Press Lyon
2. International Collaboration on HIV and Cancer Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults J Natl Cancer Inst 92 2000 1823 1830
3. O. Kirk, C. Pedersen, A. Cozzi-Lepri, F. Antunes, V. Miller, and J.M. Gatell Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy Blood 98 2001 3406 3412
4. C. Besson, A. Goubar, J. Gabarre, W. Rozenbaum, G. Pialoux, and F.P. Chatelet Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood 98 2001 2339 2344
5. Miralles P, Berenguer J, Rubio R, Ribera JM, Antela A, Santos J, et al. Characteristics and outcome of AIDS-related non-hodgkin's lymphoma before and after the introduction of HAART (GESIDA 23/01). 10th Conference of Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston. Poster 802.
6. J.T. Navarro, F. Vall-Llovera, J.L. Mate, M. Morgades, E. Feliu, and J.M. Ribera Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART Haematologica 93 2008 149 150
7. J.T. Navarro, J.M. Ribera, A. Oriol, J. Romeu, G. Sirera, and J.L. Mate Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma Leuk Lymphoma 43 2002 1837 1842
8. A. Oriol, J.M. Ribera, S. Brunet, E. Del Potro, E. Abella, and J. Esteve Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study Haematologica 90 2005 990 992
9. J.M. Ribera, J.T. Navarro, A. Oriol, A. López-Guillermo, A. Sureda, and E. Abella Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease AIDS 16 2002 1973 1976
10. J.M. Ribera, and J.T. Navarro Human immunodeficiency virus-related non-Hodgkin's lymphomas Haematologica 93 2008 1129 1132
11. J.M. Ribera, A. Oriol, M. Morgades, E. González-Barca, P. Miralles, and A. López-Guillermo Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: Results of a phase II trial Br J Haematol 140 2008 411 419
12. P. Miralles, J. Berenguer, J.M. Ribera, R. Rubio, B. Mahillo, and M.J. Tellez Prognosis of AIDS-related systemic non-hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on Tumor-related factors J Acquir Immune Defic Syndr 44 2006 167 173
13. D. Serrano, R. Carrión, P. Balsalobre, P. Miralles, J. Berenguer, and I. Buño HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation Exp Hematol 33 2005 487 494
14. J. Cortes, D. Thomas, A. Rios, C. Koller, S. O'Brien, and S. Jeha Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia Cancer 94 2002 1492 1499
15. E.S. Wang, D.J. Straus, J. Teruya-Feldstein, J. Qin, C. Portlock, and C. Moskowitz Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma Cancer 98 2003 1196 1205
16. A. Oriol, J.M. Ribera, J. Bergua, E. Giménez-Mesa, C. Grande, and J. Esteve High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma. Comparison of results in human immunodeficiency virus-infected and noninfected patients Cancer 113 2008 117 125
17. P. Miralles, J. Berenguer, J.M. Ribera-Santasusana, F. Calvo, J. Díaz-Mediavilla, and J.L. Díez-Martín GESIDA/PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients Med Clin (Barc) 130 2008 300 311
18. D. Sarker, C. Thirlwell, M. Nelson, B. Gazzard, and M. Bower Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma AIDS 17 2003 861 865
19. A. Spina, E. Chimienti, M. Martellotta, E. Zanet, A. Lleschi, and V. Canzonieri Phase II study of intrathecal long acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in HIV-related non-Hodgkin's lymphomas Farmaci 32 2008 1 8
20. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. V.1.2007. Carcinomatous/Lymphomatous Meningitis: CLMEN-1. Disponible en: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
21. Quijano S, López A, Sancho JM, Panizo C, Debén G, Castilla C, et al. Identification of leptomeningeal disease in aggressive b-cell non-hodgkin's lymphoma: Improved sensitivity of flow cytometry. J Clin Oncol. En prensa 2009.
22. N. Tomita, F. Kodama, H. Kanamori, S. Motomura, and Y. Ishigatsubo Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma Cancer 95 2002 576 580
23. A. McMillan Central nervous system-directed preventative therapy in adults with lymphoma Br J Haematol 131 2005 13 21
24. P.L. Zinzani, M. Magagnoli, G. Frezza, G. Prologo, F. Gherlinzoni, and M. Bendandi Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: The Bologna experience Leuk Lymphoma 32 1999 571 576
25. A. Hollender, S. Kvaloy, O. Nome, E. Skovlund, K. Lote, and H. Holte Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model Ann Oncol 13 2002 1099 1107
26. C. Haioun, C. Besson, E. Lepage, C. Thieblemont, D. Simon, C. Rose Groupe d'Etudes des Lymphomes de l'Adulte Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients Ann Oncol 11 2000 685 690
27. V. Boehme, S. Zeynalova, M. Kloess, M. Loeffler, U. Kaiser, and M. Pfreundschuh Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann Oncol 18 2007 149 157
28. P. Feugier, J.M. Virion, H. Tilly, C. Haioun, G. Marit, and M. Macro Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab Ann Oncol 15 2004 129 133
29. M.C. Chamberlain, P. Kormanik, S.B. Howell, and S. Kim Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases Arch Neurol 52 1995 912 917
30. Canales MA, Peñarrubia MJ, Salar A, Díaz JA, Ferreiro JJ, Ferrer S, et al. Efficacy and safety of intrathecal liposomal cytarabine injection given prophylactically in patients with high-risk diffuse large B-cell lymphoma: a report of 24 patients in Spain [resumen 1211]. Haematoló gica. 2008; 93 Suppl 1: 471.
31. D. Mazhar, J. Stebbing, and M. Bower Non-Hodgkin's lymphoma and the CNS: Prophylaxis and therapy in immunocompetent and HIV-positive individuals Expert Rev Anticancer Ther 6 2006 335 341
32. J.M. Sancho, M. Morgades, N. Alonso, G. Deben, A. Fernández de Sevilla, and L. Vázquez Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain Med Clin (Barc) 131 2008 441 446
33. M.J. Glantz, S. LaFollette, K.A. Jaeckle, W. Shapiro, L. Swinnen, and J.R. Rozental Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis J Clin Oncol 17 1999 3110 3116
34. D. Mazhar, J. Stebbing, R. Lewis, M. Nelson, B.G. Gazzard, and M. Bower The management of meningeal lymphoma in patients with HIV in the era of HAART: Intrathecal depot cytarabine is effective and safe Blood 107 2006 3412 3414
35. E. Jabbour, S. O'Brien, H. Kantarjian, G. García-Manero, A. Ferrajoli, and F. Ravandi Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia Blood 109 2007 3214 3218